CrossrefInfokarte
Can We Extend Beyond 2 Years of Adjuvant ALK TKI Established by ALINA and ELEVATE in Resected Early Stage ALK+ NSCLC a Disease with High Predilection for CNS Metastasis with Novel Clinical Trial Designs?
Lung Cancer: Targets and Therapy · 2026-09 · Volume 17 · 1-8
DOI: 10.2147/lctt.s642874 ↗Abstract
Kein Abstract verfügbar.
EUVIMED